Begin main content

Open Calls for Patient Input

This page lists Common Drug Review (CDR) drug applications received by CADTH and the deadlines for filing patient group input for each drug. For more information about how to provide input, please visit the CDR Patient Input page

Ilumya (tildrakizumab )

Indications: Psoriasis, moderate to severe plaque

Call For Patient Input: June 11, 2019

Patient Input Closed: July 31, 2019

TBC (tafamidis)

Indications: transthyretin-mediated amyloidosis

Call For Patient Input: June 5, 2019

Patient Input Closed: July 25, 2019

TBC (upadacitinib)

Indications: Arthritis, Rheumatoid

Call For Patient Input: May 31, 2019

Patient Input Closed: July 22, 2019

Monoferric (Iron (III) Isomaltoside 1000)

Indications: iron deficiency anemia

Call For Patient Input: May 29, 2019

Patient Input Closed: July 18, 2019

TBC (esketamine hydrochloride )

Indications: Major depressive disorder (MDD), adults

Call For Patient Input: May 27, 2019

Patient Input Closed: July 16, 2019

TBC (ravulizumab )

Indications: Paroxysmal nocturnal hemoglobinuria.

Call For Patient Input: May 27, 2019

Patient Input Closed: July 16, 2019

Vascepa (icosapent ethyl)

Indications: Ischemic events in statin-treated patients

Call For Patient Input: May 17, 2019

Patient Input Closed: July 9, 2019

Takhzyro (lanadelumab)

Indications: Hereditary angioedema, prevention

Call For Patient Input: April 30, 2019

Patient Input Closed: June 19, 2019

Benlysta (Belimumab)

Indications: systemic lupus erythematosus

Call For Patient Input: April 30, 2019

Patient Input Closed: June 19, 2019

Onstryv (safinamide)

Indications: Parkinson's disease

Call For Patient Input: April 30, 2019

Patient Input Closed: June 19, 2019